<table>
<thead>
<tr>
<th>action</th>
<th>automatic vs. controlled</th>
<th>Ashworth scale, 50</th>
<th>Autism Spectrum Disorders (ASD), 219</th>
</tr>
</thead>
<tbody>
<tr>
<td>control of, 103</td>
<td>performance, 103</td>
<td>Asperger’s disorder, 217, 218</td>
<td>autonomic dysfunction, 5, 25, 37, 48, 133, 153–5, 158</td>
</tr>
<tr>
<td>inhibitory control deficits, 103</td>
<td>lack of conscious control over, 103</td>
<td>and intellectual disability, 224–225</td>
<td>autosomal dominant inheritance 38</td>
</tr>
<tr>
<td>action tremor, 30</td>
<td>activities of daily living (ADLs), 143</td>
<td>clinical description, 218–219</td>
<td>Huntington’s disease, 162</td>
</tr>
<tr>
<td>lack of conscious control over, 103</td>
<td>activities of daily living (ADLs) score, 148</td>
<td>compared with cerebral palsy, 222–223</td>
<td>baclofen</td>
</tr>
<tr>
<td>activities of daily living (ADLs) score, 148</td>
<td>Activity Scale for Kids (ASK), 205</td>
<td>diagnostic criteria (DSM-IV-TR), 219</td>
<td>intrathecal injections, 47–49, 194</td>
</tr>
<tr>
<td>addiction, 88</td>
<td>intrathecal control of spasticity, 47</td>
<td>early diagnosis of motor dysfunction, 227</td>
<td>intrathecal pump, 39–40</td>
</tr>
<tr>
<td>akinesia, 30, 40, 60, 62, 82, 162, 170</td>
<td>PAG-pure akinesia with gait freezing (PAGF), 154</td>
<td>inter-professional management issues, 226</td>
<td>oral, 39, 194</td>
</tr>
<tr>
<td>PSP-pure akinesia with gait freezing (PAGF), 154</td>
<td>alcohol</td>
<td>management of motor dysfunction, 225–226, 227</td>
<td>pallidus, 111</td>
</tr>
<tr>
<td>intrathecal control of spasticity, 47</td>
<td>alien hand syndrome, 103</td>
<td>motor dysfunction, 221–222</td>
<td>basal ganglia 1</td>
</tr>
<tr>
<td>alien hand syndrome, 103</td>
<td>alpha-synuclein protein component of Lewy bodies, 140</td>
<td>multidisciplinary interventions, 227</td>
<td>actions of dopamine, 3</td>
</tr>
<tr>
<td>alpha-synuclein protein pathology 155 multiple system atrophy, 155</td>
<td>alpha-synuclein protein</td>
<td>neurobiology, 219–221</td>
<td>anatomy in the normal state, 1–2</td>
</tr>
<tr>
<td>alprazolam, 30</td>
<td>apraxia, 75, 82, 153, 155, 157, 158</td>
<td>aspiration pneumonia, 85</td>
<td>associative loop, 1</td>
</tr>
<tr>
<td>alternate and augmentative communication (AAC), 114, 118–119</td>
<td>apraxia, 25, 158</td>
<td>assistive speech devices, 114</td>
<td>changes in activity in Parkinson’s disease, 5</td>
</tr>
<tr>
<td>amantadine, 26, 158</td>
<td>aquatic physiotherapy, 193–194</td>
<td>ataxia, 75, 82, 153, 155, 157, 158</td>
<td>classical amplitude model of physiology, 2–4</td>
</tr>
<tr>
<td>alcohol</td>
<td>Ashworth scale, 50</td>
<td>See also cerebellar ataxia, Friedreich ataxia, spino cerebellar ataxia</td>
<td>direct pathway, 2–3</td>
</tr>
<tr>
<td>intrathecal control of spasticity, 47</td>
<td>action tremor, 30</td>
<td>atenolol, 30</td>
<td>effects of basal ganglia pathology, 1</td>
</tr>
<tr>
<td>alien hand syndrome, 103</td>
<td>anoxic ischemic event, 195</td>
<td>athetosis, 111</td>
<td>feedback circuits, 3</td>
</tr>
<tr>
<td>alpha-synuclein protein</td>
<td>use in Parkinson’s disease, 26–27</td>
<td>attention</td>
<td>functional loops, 1</td>
</tr>
<tr>
<td>component of Lewy bodies, 140</td>
<td>anticholinergic side effects, 27</td>
<td>control of, 103</td>
<td>functional organization, 1, 2–4</td>
</tr>
<tr>
<td>multiple system atrophy, 155</td>
<td>anticonvulsant drugs, 39</td>
<td>attention deficit and disruptive behavior disorders (DSM-IV-TR), 217</td>
<td>functions of the fronto-striatal circuits, 95–96</td>
</tr>
<tr>
<td>alprazolam, 30</td>
<td>anxiety, 88</td>
<td>attention tests, 98</td>
<td>indirect pathway, 2–3</td>
</tr>
<tr>
<td>acute and augmentative communication (AAC), 114, 118–119</td>
<td>Anxiety Status Inventory, 99</td>
<td>atypical autism, 219</td>
<td>influences on thalamocortical activity, 2–3</td>
</tr>
<tr>
<td>amantadine, 26, 158</td>
<td>anxiety testing, 99</td>
<td>autism, 217, 218</td>
<td>limbic loop, 1</td>
</tr>
<tr>
<td>effects on levodopa-induced dyskinesia, 29</td>
<td>apathy, 88</td>
<td>and intellectual disability, 224–225</td>
<td>limitations of the classical amplitude model, 3–4</td>
</tr>
<tr>
<td>Parkinson’s disease medication, 29</td>
<td>Apathy Scale, 99</td>
<td>clinical description, 218–219</td>
<td>motor loop, 1, 2</td>
</tr>
<tr>
<td>side effects, 29</td>
<td>aphasia, 98</td>
<td>compared with cerebral palsy, 222–223</td>
<td>oculomotor loop, 1</td>
</tr>
<tr>
<td>anal fissure, 44</td>
<td>apomine, 145</td>
<td>diagnostic features (DSM-IV-TR), 219</td>
<td>orbitofrontal loop, 1</td>
</tr>
<tr>
<td>ankle-foot orthotics, 195</td>
<td>apomorphine, 7, 28</td>
<td>early diagnosis of motor dysfunction, 227</td>
<td>pathology associated with movement disorders, 1</td>
</tr>
<tr>
<td>use in Friedreich ataxia, 194–195</td>
<td>apraxia, 25, 158</td>
<td>inter-professional management issues, 226</td>
<td>physiology, 2–4</td>
</tr>
<tr>
<td>anterior cervical rhizotomy, 49</td>
<td>autistic spectrum disorders</td>
<td>management of motor dysfunction, 225–226, 227</td>
<td>procedural and skill learning, 104</td>
</tr>
<tr>
<td>anticholinergic drugs, 39, 158</td>
<td>(ASD), 219</td>
<td>motor dysfunction, 221–222</td>
<td>basal ganglia dysfunction</td>
</tr>
<tr>
<td>use in Parkinson’s disease, 26–27</td>
<td>autonomic dysfunction, 5, 25, 37, 48</td>
<td>multidisciplinary interventions, 227</td>
<td>movement disorders associated with, 94</td>
</tr>
<tr>
<td>anticholinergic side effects, 27</td>
<td>baclofen</td>
<td>neurobiology, 219–221</td>
<td>Beck Anxiety Inventory, 99</td>
</tr>
<tr>
<td>anticonvulsant drugs, 39</td>
<td>intrathecal injections, 47–49, 194</td>
<td>Autism Behavior Checklist, 223</td>
<td>Beck Depression Inventory, 99</td>
</tr>
<tr>
<td>anxiety, 88</td>
<td>intrathecal pump, 39–40</td>
<td></td>
<td>Behaviour Observation Scale Huntington, 83</td>
</tr>
<tr>
<td>Anxiety Status Inventory, 99</td>
<td>oral, 39, 194</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>behavioral disturbances with movement disorders, 88</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>benzhexol, 26</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>benzodiazipines, 39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>benzotropine, 26, 39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Berg Balance Scale, 168</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>beta-blockers, 39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>biopsychosocial model, 126</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>biological dimension of movement disorders, 126</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>family dimension of movement disorders, 127</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>psychological/emotional dimension of movement disorders, 126</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>religious/spiritual/existential dimension of health challenges, 127</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>social/environmental dimension of health challenges, 127</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bladder dysfunction, 88–89</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>blepharospasm, 40, 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>botulinum toxin treatment, 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>body-image disorders, 86</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BOLD magnetic resonance imaging (fMRI), 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s disease, 7–8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boston Naming Test (BNT), 98, 116</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>botulinum toxin, 44–45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>botulinum toxin A, 30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>botulinum toxin treatment blepharospasm, 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cervical dystonia, 39, 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dystonia, 174</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>essential tremor, 46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>focal dystonias, 45–46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>for spasticity in Friedreich ataxia, 194</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hemifacial spasm, 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>injection procedure for dystonias, 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>injections, 40</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>limb-task specific dystonias, 45–46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s disease dystonias, 46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>spastic dystonias, 46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tremor, 46–47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>writer’s cramp, 45–46</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bowel dysfunction, 88–89</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bradykinesia, 1, 82</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and BOLD fMRI imaging, 8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and tremor, 30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in Huntington’s disease, 10–11, 162</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in parkinsonian syndromes, 152</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>in Parkinson’s disease, 7, 14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>movement strategy training, 60</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>neuropsychology of, 103</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>brain basal ganglia anatomy in the normal state, 1–2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>brain injury dystonias associated with, 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>brainstem, 3, 20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brief Psychiatric Rating Scale, 99</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>California Verbal Learning Test, 98</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cambridge Neuropsychological Test Automated Battery (CANTAB), 99</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canadian Occupational Performance Measure (COPM), 73, 205</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cabergoline, 27</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>carbidopa, 28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>carboxylic acid, 47</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>care-givers support for, 89–90, 165–166</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>casting to prevent contractures, 50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>catatonia, 25</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>catechol-O-methyltransferase (COMT) inhibitors, 26</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>combination with levodopa, 28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>entacapone, 28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>indications for use, 28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s disease medications, 28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>side effects, 28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tolcapone, 28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>caudate nucleus, 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>central nervous system, 39, 132, 174, 188</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>central sleep apnea, 159</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>centromedian nucleus, 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cerebellar ataxia, 153</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cerebellar deficits 187</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cerebellar outflow tremor, 39</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cerebellar tremor, 30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cerebellum, 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cerebral cortex, 1–3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cerebral palsy, 40, 194, 195, 217, 218</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>and intellectual disability, 224–225</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>compared with autism spectrum disorders, 222–223</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dystonia associated with, 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>early diagnosis of motor dysfunction, 227</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>importance of post-operative rehabilitation in SEMLS, 203</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>indications for single-event multilevel surgery (SEMLS), 203</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>inter-professional management issues, 226</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>management of motor dysfunction, 225–226, 227</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>multidisciplinary interventions, 227</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>progressive musculoskeletal pathology, 203</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rehabilitation principles, 134–136</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SEMLS procedure and rehabilitation process, 203–215</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cervical dystonia, 39, 40, 44, 45, 112</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>botulinum toxin treatment, 39, 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>common patterns, 45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rehabilitation strategies, 176–177</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Childhood Autism Rating Scale, 223</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>childhood disintegrative disorder, 219</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>children with chronic movement disorders 136</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rehabilitation principles, 134–136</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Children’s Assessment of Participation and Enjoyment (CAPE), 205</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cholinergic neurons, 5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chorea, 25, 82, 111, 162</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>causes, 32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>definition of chorea, 32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dysarthria associated with, 111–112</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>medical management, 32–33</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>symptoms, 32</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Global Impression Scale, 99</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clinical utility of outcome measures, 237</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clinimetrics, 234–236</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>responsiveness, 236</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>validity, 236</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clock drawing test, 98</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clonazepam, 30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clonidine, 194</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clozapine, 30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cognitive effects in movement disorders, 94</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cognitive functions networks supporting, 95</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cognitive–linguistic disorders, 115</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>assessment, 115–116</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>management, 116</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>communication assistance, 85</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>alternate and augmentative communication (AAC), 114, 118–119</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>assistive speech devices, 114</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>communication difficulties parkinsonian syndromes, 157</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Communication Effectiveness Survey (CES), 116</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Communication Function Classification System (CFCS), 223</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>communication management Friedreich ataxia, 195</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>See also language difficulties; speech difficulties.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Communicative Abilities in Daily Living (CADI-L2), 116</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>community care parkinsonian syndromes, 158</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>complex regional pain syndromes (CRPS) intrathecal baclofen therapy, 48–49</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>concurrent processing, 103</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>constipation, 89</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>constraint induced movement therapy (CIMT), 50</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>construction tests, 98</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>contractures, 49, 50, 188</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>therapies, 193</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>coprolalia, 112</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>corticobasal degeneration, 152, 153</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>neuropsychology, 101–102</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tau protein pathology, 155</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>corticobasal syndrome clinical features, 155</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dysthria, 49, 50, 188</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gait and mobility rehabilitation issues, 156–157</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>home and environmental assessment, 157</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>medical management, 158–159</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>multidisciplinary team care, 159</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nursing and community care, 158 speech and communication difficulties, 157 therapeutic strategies, 156 upper and lower limb functional issues, 157</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>deep-brain stimulation (DBS), 5, 26, 31</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dantrolene sodium, 194</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delis-Kaplan first letter and category verbal fluency test, 98</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dementia in Parkinson’s disease assessment tools, 98–99</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dementia with Lewy bodies, 153</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>depression, 88</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Friedreich Ataxia Rating Scale (FARS), 187, 190
Friedreich ataxia rehabilitation
ankle–foot orthoses, 194–195
aquatic physiotherapy, 193–194
assessment, 189
balance and posture assessment, 190
balance training, 192
cardiovascular exercises, 191–192
communication management, 195
compensation for impaired
proprioception, 190
coordination and strength
assessment, 189–190
functional communication
assessment, 190
gait assistive devices, 191
gait re-education, 191
hearing assessment, 190
home environment adaptation, 195–196
impact of sensory changes, 190
improving core stability, 192
maintenance of standing, 195
management of scoliosis, 192–193
motor activity assessment, 189–190
multidisciplinary team
involvement, 196
pain assessment, 190
practising transfers from one
position to another, 191
respiratory system considerations, 192
spasticity management, 194
speech assessment, 190
stretching, 193
studies, 188–189
swallowing assessment, 190
swallowing management, 195
therapy outcome measures, 190
upper-limb interventions, 193
vision assessment, 190
wheelchair prescription, 195
Frontal Assessment Battery (FAB), 98
fronto-striatal network functions,
95–96
frontotemporal dementia
syndromes, 155
behavioral variant, 155
in PSP patients, 155
frontotemporal dementia with
parkinsonism associated with
chromosome-17, 153
Functional Assessment of
Communication Skills for Adults
(ASHA FACS), 116
functional imaging techniques, 1
Functional Independence Measure
(FIM), 83, 187, 188
Functional Mobility Scale (FMS), 135
functional MRI (fMRI) studies
Huntington’s disease, 11
Parkinson’s disease, 7–8
functional neuroimaging
findings in Parkinson’s disease, 5–8
use in neuropsychology, 94
functional neurosurgery
dystonia, 39–40
esential tremor, 38–39
future development of surgical
options, 40
Parkinson’s disease, 36–38
role in movement disorder
management, 36
GABA medium spiny neurons, 164
GABAergic neurons
striatum, 2–3, 8
gabapentin, 30, 39
gait and mobility rehabilitation
parkinsonian syndromes, 156–157
gait problems
physiotherapy interventions, 61
gamma knife thalamotomy, 31
general practitioner, 145
generalized dystonia
rehabilitation strategies, 179–181
genetic counseling 86
Huntington’s disease, 86
geriatrician, 145
Gilles de la Tourette syndrome, 14, 112
neuropsychological studies, 19–20
pathophysiology, 19–20
Gillette Gait Index (GGI), 203
glial alpha-synuclein protein
pathology
multiple system atrophy, 155
global rating of change scales,
237–240
globus pallidus, 1
globus pallidus externa, 1–3
globus pallidus interna, 1–3
goal attainment scaling (GAS),
240–241
Gordon’s 11 step model of functional
health patterns, 83
Graded Naming Test, 98
Gross Motor Function Classification
System (GMFCS), 135, 203, 223
Gross Motor Function Measure
(GMFM), 135
ground reaction ankle-foot orthoses,
206–207
H$_3$[15O] PET studies
Parkinson’s disease, 7
habitual responses
inhibitory control deficits, 103
hallucinations, 88

<table>
<thead>
<tr>
<th>Exercise</th>
<th>Physiotherapy interventions, 58–59, 61–62</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extralumbar ramiesecomy</td>
<td>45</td>
</tr>
<tr>
<td>Extralumbar selective sectioning of dorsal rami</td>
<td>49</td>
</tr>
<tr>
<td>Extrapyramidal bradykinesia</td>
<td>152</td>
</tr>
<tr>
<td>Extrapyramidal rigidity</td>
<td>154</td>
</tr>
<tr>
<td>Extrapyramidal system</td>
<td>110</td>
</tr>
<tr>
<td>Fall prevention</td>
<td>84–85</td>
</tr>
<tr>
<td>Fatigue</td>
<td>82</td>
</tr>
<tr>
<td>Fatigue Severity Scale</td>
<td>99</td>
</tr>
<tr>
<td>FDOPA ([18F]-fluorodopa) PET studies</td>
<td>206</td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td>7</td>
</tr>
<tr>
<td>Parkinson’s disease, 5–6</td>
<td>135</td>
</tr>
<tr>
<td>Fatigue</td>
<td>155</td>
</tr>
<tr>
<td>Familial tremor</td>
<td>31</td>
</tr>
<tr>
<td>Focal dystonias</td>
<td>44, 45, 112</td>
</tr>
<tr>
<td>Botulinum toxin treatment</td>
<td>45–46</td>
</tr>
<tr>
<td>Freezing of gait</td>
<td>25, 46, 82</td>
</tr>
<tr>
<td>FSP-pure akinesia with gait freezing (PAGF)</td>
<td>154</td>
</tr>
<tr>
<td>Freezing of Gait Scale</td>
<td>83</td>
</tr>
<tr>
<td>Friedreich ataxia</td>
<td>185</td>
</tr>
<tr>
<td>Age of onset</td>
<td>185</td>
</tr>
<tr>
<td>Auditory pathway abnormality</td>
<td>186–187</td>
</tr>
<tr>
<td>Capacity to participate in daily activities</td>
<td>187</td>
</tr>
<tr>
<td>Cerebellar deficits</td>
<td>187</td>
</tr>
<tr>
<td>Clinical features</td>
<td>185</td>
</tr>
<tr>
<td>Cognitive effects</td>
<td>187</td>
</tr>
<tr>
<td>Course of the disease</td>
<td>185</td>
</tr>
<tr>
<td>Dysarthria</td>
<td>186</td>
</tr>
<tr>
<td>Effect of poor foot alignment</td>
<td>187–188</td>
</tr>
<tr>
<td>Equinovarus deformity</td>
<td>187–188</td>
</tr>
<tr>
<td>FXN gene mutations</td>
<td>185</td>
</tr>
<tr>
<td>Hearing problems</td>
<td>186–187</td>
</tr>
<tr>
<td>Impact on mobility</td>
<td>185–186</td>
</tr>
<tr>
<td>Inheritance pattern</td>
<td>185</td>
</tr>
<tr>
<td>Lower-limb spasticity and equinovarus deformity</td>
<td>187–188</td>
</tr>
<tr>
<td>Management approaches</td>
<td>185</td>
</tr>
<tr>
<td>Measures of functional capacity</td>
<td>187</td>
</tr>
<tr>
<td>Neuropathology</td>
<td>185</td>
</tr>
<tr>
<td>Prevalence</td>
<td>185</td>
</tr>
<tr>
<td>Psychomotor dysfunction</td>
<td>187</td>
</tr>
<tr>
<td>Speech and language effects</td>
<td>186</td>
</tr>
<tr>
<td>Visual problems</td>
<td>187</td>
</tr>
<tr>
<td>Friedreich Ataxia Rating Scale (FARS)</td>
<td>187, 190</td>
</tr>
<tr>
<td>Friedreich ataxia rehabilitation</td>
<td>194–195</td>
</tr>
<tr>
<td>Aquatic physiotherapy</td>
<td>193–194</td>
</tr>
<tr>
<td>Assessment</td>
<td>189</td>
</tr>
<tr>
<td>Balance and posture assessment</td>
<td>190</td>
</tr>
<tr>
<td>Balance training</td>
<td>192</td>
</tr>
<tr>
<td>Cardiovascular exercises</td>
<td>191–192</td>
</tr>
<tr>
<td>Communication management</td>
<td>195</td>
</tr>
<tr>
<td>Compensation for impaired proprioception</td>
<td>190</td>
</tr>
<tr>
<td>Coordination and strength assessment</td>
<td>189–190</td>
</tr>
<tr>
<td>Functional communication assessment</td>
<td>190</td>
</tr>
<tr>
<td>Gait assistive devices</td>
<td>191</td>
</tr>
<tr>
<td>Gait re-education</td>
<td>191</td>
</tr>
<tr>
<td>Hearing assessment</td>
<td>190</td>
</tr>
<tr>
<td>Home environment adaptation</td>
<td>195–196</td>
</tr>
<tr>
<td>Impact of sensory changes</td>
<td>190</td>
</tr>
<tr>
<td>Improving core stability</td>
<td>192</td>
</tr>
<tr>
<td>Maintenance of standing</td>
<td>195</td>
</tr>
<tr>
<td>Management of scoliosis</td>
<td>192–193</td>
</tr>
<tr>
<td>Motor activity assessment</td>
<td>189–190</td>
</tr>
<tr>
<td>Multidisciplinary team involvement</td>
<td>196</td>
</tr>
<tr>
<td>Pain assessment</td>
<td>190</td>
</tr>
<tr>
<td>Practising transfers from one position to another</td>
<td>191</td>
</tr>
<tr>
<td>Respiratory system considerations</td>
<td>192</td>
</tr>
<tr>
<td>Spasticity assessment</td>
<td>190</td>
</tr>
<tr>
<td>Spasticity management</td>
<td>194</td>
</tr>
<tr>
<td>Speech assessment</td>
<td>190</td>
</tr>
<tr>
<td>Stretching exercises</td>
<td>191–192</td>
</tr>
<tr>
<td>Stretching</td>
<td>193</td>
</tr>
<tr>
<td>Studies</td>
<td>188–189</td>
</tr>
<tr>
<td>Swallowing assessment</td>
<td>190</td>
</tr>
<tr>
<td>Swallowing management</td>
<td>195</td>
</tr>
<tr>
<td>Therapy outcome measures</td>
<td>190</td>
</tr>
<tr>
<td>Upper-limb interventions</td>
<td>193</td>
</tr>
<tr>
<td>Vision assessment</td>
<td>190</td>
</tr>
<tr>
<td>Wheelchair prescription</td>
<td>195</td>
</tr>
<tr>
<td>Frontal Assessment Battery (FAB)</td>
<td>98</td>
</tr>
<tr>
<td>Frontostriatal network functions</td>
<td>95–96</td>
</tr>
<tr>
<td>Frontotemporal dementia syndromes</td>
<td>155</td>
</tr>
<tr>
<td>Behavioral variant</td>
<td>155</td>
</tr>
<tr>
<td>In PSP patients</td>
<td>155</td>
</tr>
<tr>
<td>Frontotemporal dementia with parkinsonism associated with chromosome-17</td>
<td>153</td>
</tr>
<tr>
<td>Functional Assessment of Communication Skills for Adults (ASHA FACS)</td>
<td>116</td>
</tr>
<tr>
<td>Functional imaging techniques</td>
<td>1</td>
</tr>
<tr>
<td>Functional Independence Measure (FIM)</td>
<td>83, 187, 188</td>
</tr>
<tr>
<td>Functional Mobility Scale (FMS)</td>
<td>135</td>
</tr>
</tbody>
</table>

© in this web service Cambridge University Press www.cambridge.org
Hamilton Anxiety Rating Scale, 99
Hamilton Depression Rating Scale, 99
health related quality of life (HRQOL),
231–234
hearing problems
in Friedreich ataxia, 186–187
hemidystonia, 40
hemifacial spasm, 44–5
hereditary spastic paraplegia
rehabilitation principles, 134–136
heredodegenerative parkinsonism, 25
Hoehn and Yahr scale, 236
holistic management of movement
disorders, 25
Holmes tremor, 39
home assessment
parkinsonian syndromes, 157
Hospital Anxiety and Depression
Scale, 99
Huntingtin protein, 162–164
Huntington’s disease, 153
abnormal CAG sequence, 162
age of onset, 162
autosomal dominant inheritance, 162
bradykinesia, 10–11
cerebral glucose metabolism, 9–10
Cognitive deterioration, 33
definition of chorea, 32
description, 32–33
diagnosis, 162
functions of the social worker,
125–126
Genetic cause, 162
Genetic counseling, 86
impairments associated with, 162
influence of CAG repeat length, 9
medical management, 32–33
motor disorder management, 33
mutated Huntingtin protein,
162–164
neurobehavioral disorder
management, 33
neuropathology, 162–164
neurophysiological studies, 18–19
neuropsychology, 102
Pathophysiology, 8–11, 18–19
prodomal symptoms, 162
rate of disease progression, 9
straital degeneration, 8–11
symptoms, 32–33
Huntington’s Disease Family Concerns
and Strategies survey, 89
Huntington’s disease rehabilitation
composition of the rehabilitation
team, 166–167
eye stage of disease, 168–169
evidence related to effective models
for rehabilitation, 167
family-centered approach, 165–166
goals of rehabilitation, 170–171
late stages of disease, 170
mid stages of disease, 169–170
prodomal stage, 167–168
rehabilitation model, 164–165
support for care-givers, 165–166
treatments based on
neuropathological knowledge,
162–164
hyperhidrosis, 44
hyperkinetic dysarthria,
111–113
hyperkinetic movement disorders, 25
hypersexuality, 88
hypokinesia, 82, 162
hypokinetic dysarthria, 110–111
hypokinetic movement disorders, 25
idiopathic dystonia, 174
idiopathic focal dystonias, 45
idiopathic Parkinson’s disease, 139
See also Parkinson’s disease.
impulse-control disorder, 88
incoordination, 162
inhibitory control deficits, 103
intellectual disability, 217, 218
and autism spectrum disorders,
224–225
and cerebral palsy, 224–225
early diagnosis of motor
dysfunction, 227
inter-professional management
issues, 226
management of motor dysfunction,
225–226, 227
multidisciplinary interventions, 227
intention tremor, 30
International Classification of
Functioning, Disability and
Health (ICF), 57, 81, 113
framework, 232–233
International Statistical Classification
of Diseases and Related Health
Problems, 10th Revision (ICD-10,
1992), 217
internet resources for people with
movement disorders, 128–129
intralateral anterior rhizotomy, 45
isometric tremor, 30
kinetic tremor, 30
language difficulties
in Friedreich ataxia, 186
laryngeal dystonia, 112
rehabilitation strategies, 179
learning disorders (DSM-IV-TR), 217
Lee Silverman Voice Treatment
(LSVT®), 114
lentiform nucleus, 1
levetiracetam, 31
levodopa, 26–7
combination with COMT
inhibitors, 28
dyskinesias associated with
long-term use, 28
formulations, 28
Parkinson’s disease medication, 28
side effects, 28
levodopa-induced dyskinesia, 16,
26, 36
effects of amantadine, 29
Lewy bodies
alpha-synuclein protein
component, 140
in Parkinson’s disease, 4, 5
pathological distribution in
Parkinson’s disease, 139–140
Lewy neurites
in Parkinson’s disease, 4, 5
limb task specific dystonias
botulinum toxin treatment, 45–46
livedo reticularis, 29
locus coeruleus, 3
Manual Abilities Classification System
(MACS), 223
manual dexterity tests, 98
Mattis Dementia Rating Scale (MDRS),
98, 101
medical management of movement
disorders
chorea, 32–33
dystonia, 31–32
holistic management, 25
Huntington’s disease, 32–33
multidisciplinary approach, 25
parkinsonian syndromes,
158–159
Parkinson’s disease, 25–30
symptomatic treatment, 25
therapeutic approach, 25
treatment of any underlying
cause, 25
tremor, 30–31
medications
management of side effects, 86
Meige’s syndrome, 39
micrographia, 104, 154
microvascular decompression of the
spinal accessory nerve, 49
Mini Mental State Examination
(MMSE), 83, 98, 148
Modified Barthel Index (MBI), 187
monoamine oxidase-B (MAO-B)
inhibitors, 26
Montgomery Asberg Depression
Rating Scale, 99
Index

Montreal Cognitive Assessment (MoCA), 98
mood assessment tools, 98
mood disorder testing, 99
motivations, 1
motor cortex, 2
motor loop of the basal ganglia, 1, 2
motor-skills disorder (DSM-IV-TR), 217
movement disorder care
importance of outcome measurement, 231
Movement Disorder Society, 26, 38, 98, 99, 128, 241
movement rehabilitation, 49–50
movement strategy training, 59–60, 62
multidisciplinary team approach to medical management of movement disorders, 25
movement disorder nurse, 81–91
neuropsychologist, 94–105
occupational therapist, 55–65
role in rehabilitation, 136–137
skills and disciplines available, 145–147
social worker, 124–129
speech pathologist, 110–119
social worker, 124–129
speech pathologist, 110–119
multidisciplinary team care
Friedreich ataxia, 196
parkinsonian syndromes, 159
speech and swallowing disorders, 85–86
multiple sclerosis rehabilitation principles, 133–134
tremor associated with, 39
multiple system atrophy, 25, 152, 153
advanced care, 156
clinical features, 155–156
diagnosis, 155
dysphagia management, 157–158
gait and mobility rehabilitation issues, 156–157
glial alpha-synuclein protein pathology, 155
home and environmental assessment, 157
medical management, 158–159
multidisciplinary team care, 159
neuropsychology, 101
nursing and community care, 158
parkinsonian symptoms, 155
prevalence, 155
speech and communication difficulties, 157
therapeutic strategies, 156
upper and lower limb functional issues, 157
multiple system degeneration, 25
musician’s cramp, 45
rehabilitation strategies, 178–179
myectomyomy of trapezius muscle, 45
myoclonus, 25, 111
impact on speech, 112
nadolol, 30
National Parkinson Foundation, 241
neuroacanthocytosis, 153
neuroleptic medications, 112
neurologist, 145
neurophysiological studies, 14
dystonia, 17–18
Gilles de la Tourette syndrome, 19–20
Huntington’s disease, 18–19
Parkinson’s disease, 14–17
pathophysiological mechanisms of movement disorders, 20
neuroplasticity and relearning capacity, 136
Neuropsychiatric Inventory (NPI), 98, 99
neuropsychological assessment commonly used tests and scales, 98–99
differential diagnosis of movement disorders, 97
impact of functional neurosurgery, 97
level of daily functioning, 97–98
longitudinal profile of movement disorders, 97
practical considerations, 99–100
reasons for, 96–98
role in rehabilitation programs, 98
neuropsychological principles application to movement disorder rehabilitation, 104–105
neuropsychology definition, 94–95
executive function models, 95
functional neuroimaging, 94
functions of the frontal-striatal network, 95–96
networks supporting cognitive functions, 95
transcranial magnetic stimulation (TMS), 94–95
neuropsychology of movement disorders, 100
automatic vs. controlled performance of action, 103
basal ganglia dysfunction, 94
bradykinesia, 103
cognitive and motor functional effects, 94
concurrent processing difficulty, 103
consequences of executive overload, 103
corticobasal degeneration, 101–102
deficits in inhibitory control, 103
doing two things at once, 103
dystonia, 102
essential tremor, 102
higher motor control in movement disorders, 102–104
Huntington’s disease, 102
internal vs. external control of attention and action, 103
lack of conscious control over action, 103
multiple system atrophy, 101
non-motor symptoms, 94
Parkinson’s disease, 100–101
primary dystonia, 102
procedural learning, 104
progressive supranuclear palsy, 101
similarities across conditions, 102
skill learning, 104
speed of processing and motor preparation, 103
temporal processing, 103
neurorehabilitation, 131
Neurosensory Centre Comprehensive Examination for Aphasia (NCCEA), 116
neurotransmitters, 100, 158
dopamine, 27
nigrostriatal degeneration in Parkinson’s disease, 4
nigrostriatal pathway, 2
nimodipine, 30
NMDA glutamate receptor antagonist 29
amantadine, 29
nocturia, 87
noradrenaline, 159
noradrenergic neurons, 5
normal pressure hydrocephalus, 25, 153
nucleus accumbens, 1
nursing aims of movement disorder nursing, 82–83
assessing depression and anxiety, 88
assessing sexual dysfunction, 88
assisting communication, 85
behavioral disturbances with movement disorders, 88
clinical research and the nursing role, 90
education and health promotion, 86
encouraging physical activities, 84
fall prevention, 84–85
Gordon’s 11 step model of functional health patterns, 83
Index

helping patients cope with bladder and bowel dysfunction, 88–89
importance in movement disorder care, 91
interventions during the course of the disease, 83–85
interventions in later stages, 85
managing medication side effects, 86
medication management, 86
monitoring nutrition, 87–88
movement disorder assessment tools, 83
palliative care, 90
parkinsonian syndromes, 138
patient assessment and observation, 83
prevention of secondary complications, 86–88
promoting adaptation to new roles, 85–86
promoting independence and self-care, 85–86
promotion of quality of life, 83–85
range of impairments in people with movement disorders, 82
rehabilitation nursing, 81
role in the multidisciplinary team, 82
role of the movement disorder nurse, 81–82
supporting care-givers, 89–90
supporting movement strategies, 84
swallowing difficulty management, 85–86
nutrition, 87–88
obsessive–compulsive disorders, 88
obstructive sleep apnea, 159
occupational therapist, 72, 85
occupational therapy
evidence for effectiveness in movement disorders, 69–71
goals and values, 69
goals for different movement disorders, 77
importance of contextual information, 72
patient-centered approach, 69, 71–72
research challenges, 70–71
research studies, 69–71
role in rehabilitation of people with movement disorders, 77–79
types of interventions used, 69
underpinning principles, 71–72
use of accessible terminology and language, 72
occupational therapy process framework, 72–77
activity analysis, 74–75
assessment phase, 72–75
attitude level intervention, 77
core components, 72
goal setting, 73–74
knowledge level intervention, 76–77
levels of intervention, 72
referral on to other services, 75
roles of the occupational therapist, 72
skill level intervention, 76
treatment phase, 72–73, 75–77
off painful dystonia, 46
on-off effect of medication, 148
on-off effect with levodopa, 28
oral facial spasms, 39
orolinguo-mandibular dystonia, 112
oromandibular apraxia, 158
orthoses, 206–207
use in Friedreich ataxia, 194–195
orthostatic hypertension, 158–159
orthostatic hypotension, 85, 87
orthostatic tremor, 39
outcome measures
and the ICF model, 232–233
choosing what to measure, 232–234
clinical utility, 237
clinimetrics, 234–236
common measures used for people with movement disorders, 237
definition, 231
feasibility of use, 237
Friedreich ataxia therapies, 190
health related quality of life (HRQOL), 231–234
importance in movement disorder care, 231
interpretability, 237
non-standard measurement tools, 237–241
physiotherapy interventions, 64–65
practical considerations, 237
reasons for carrying out measurement, 231–232
reliability of measurements, 234–236
resources available, 241
responsiveness, 236
role in evidence-based practice, 231
selection case scenario, 241–240
selection criteria, 231–234
validity of measurements, 236
outreach service, 148
Oxford Geriatric Depression Scale, 88
paced auditory serial addition test, 98
pain, 82
pain management
effects of botulinum toxin, 44
surgical interventions, 36
palatopharyngolaryngeal myoclonus, 112
palilalia, 112
palliative care, 90
pallidotomy, 3, 5, 7
pantothenate kinase-associated neurodegeneration (PKAN), 48
paresthesia, 47, 48
parafascicular nucleus, 3
paresis, 82
Parkinson Neuropsychometric Dementia Assessment (PANDA), 99
parkinsonism
approach to rehabilitation, 152
dysphagia management, 157–158
gait and mobility rehabilitation issues, 156–157
home and environmental assessment, 157
list of conditions included, 152–153
medical management, 158–159
multidisciplinary team care, 159
nursing and community care, 158
speech and communication difficulties, 157
therapeutic strategies, 156
upper and lower limb functional issues, 157
See also specific syndromes.
parkinsonism
classification of types, 25
parkinsonism dementia complex of Guam, 153
Parkinson’s disease, 1
botulinum toxin treatment of dystonias, 46
changes in basal ganglia activity, 5
deep brain stimulation (DBS), 5, 36–38
description, 25
dystonia associated with, 45
effects of basal ganglia pathology, 1
functional neuroimaging findings, 5–8
functional neurosurgery, 36–38
functions of the social worker, 125
hypokinetic dysarthria, 110–111
Lewy bodies, 4, 5
Lewy neurites, 4, 5
medical management, 25–30
medical treatment algorithm, 29–30
motor symptoms, 14
neurophysiological studies, 14–17
neuropsychology, 100–101
nigrostriatal degeneration, 4
pathological distribution of Lewy bodies, 139–140
pathophysiology, 4–8, 14–17
primary parkinsonism, 25
search for neuroprotective agents, 25
search for neurorestorative treatment, 26

© in this web service Cambridge University Press

www.cambridge.org
Index

Parkinson’s disease (cont.)
- staging system, 4
- strategies to delay or manage motor complications, 26
- symptomatic treatment, 25–26
- symptoms, 25
- tests for dementia, 98–99
- therapeutic strategies, 25–26
- Parkinson’s Disease Cognitive Rating Scale (PD-CRS), 99
- Parkinson’s Disease Functional Scale (PD FS 16), 147
- Parkinson’s disease medications
  - amantadine, 29
  - anticholinergics, 26–27
  - catechol-O-methyltransferase (COMT) inhibitors, 28
  - choice of medication, 26
  - dopamine agonists, 27–28
  - entacapone, 28
  - levodopa, 28
  - monoamine oxidase-B (MAO-B) inhibitors, 26
  - rasagiline, 26
  - selegiline, 26
  - tolcapone, 28
- Parkinson’s disease rehabilitation
  - complexity of Parkinson’s disease pathology, 139–140
  - integration into multidisciplinary team care, 145–147
  - medical care model, 143–145
  - multidisciplinary team approach, 150
  - multidisciplinary team care model, 139
  - organizational structure of contact points, 147–148
  - promoting self-management, 148–150
  - theoretical basis, 140–143
- Parkinson’s Disease Sleep Scale (PDSS), 148
- Parkinson’s Fatigue Scale, 99
- Parkinson’s Quality of Life Scale (PDQ 39), 83, 147, 148
- pathological gambling, 88
- pediatric neuro-disability medical specialty, 217–218
- pedunculopontine DBS, 38
- pedunculopontine nucleus, 3, 15
- pergolide, 28
- peripheral surgical treatments, 49
- peripheral therapies
  - botulinum toxin treatment, 45–47
  - indications for, 44
  - intrathecal alcohol injection, 47
  - intrathecal baclofen therapy, 47–49
  - movement rehabilitation, 49–50
  - phenolization of nerves, 47
- physiotherapy, 49–50
  - types of, 44
  - pervasive developmental disorder not otherwise specified (PDD-NOS), 219
  - pervasive developmental disorders (PDDs), 217, 218
  - See also Asperger’s disorder; autism.
  - pes cavus, 188
- PET (positron emission tomography), 1
- PET imaging studies
  - Parkinson’s disease, 5–7
- PET imaging techniques
  - findings in Huntington’s disease, 8–11
  - pet therapy, 90
- phenolization of peripheral nerves, 47
- Physical Performance Test, 167
- physical therapy, 49–50
- physiotherapist, 85
- role in movement disorder rehabilitation, 55–57
- physiotherapy
  - clinical framework for movement disorder management, 57–58
  - exercise interventions, 58–59, 61–62
  - fall-prevention interventions, 63–64
  - gait interventions, 61
  - measuring outcomes, 64–65
  - movement strategy training, 59–60, 62
  - postural control interventions, 62–63
  - problem-orientated approach, 61–64
  - role in movement disorder management, 49–50, 55
  - transfer movement strategies, 64
  - upper limb dysfunction interventions, 64
  - picture naming tasks, 98
  - position-specific dystonia, 31
  - position-specific postural tremor, 30
  - Positive and Negative Syndrome Scale, 99
  - positron emission tomography. See PET posteroventral pallidotomy, 39
  - hypoxic parkinsonism, 153
  - post-stroke parkinsonism, 153
  - post-stroke tremor, 39
  - post-traumatic parkinsonism, 152, 153
  - post-traumatic tremor, 39
  - postural control
  - physiotherapy interventions, 62–63
  - postural instability, 82, 162
  - postural tremor, 30
  - predominant apraxia of speech, 155
  - pregabalin, 30
  - prepotent responses
    - inhibitory control deficits, 103
  - primary dystonia
    - functional neurosurgery, 39–40
  - neuropsychology, 102
- primary parkinsonism, 25
- primary somatosensory cortex, 2
- primidone, 30, 39
- procedural learning, 104
- processing speed tests, 98
- progressive non-fluent aphasia, 155
- progressive supranuclear gaze palsy, 25
- progressive supranuclear palsy (PSP), 152, 153
- clinical subtypes, 152
- diagnosis, 152
- dysphagia management, 157–158
- gait and mobility rehabilitation issues, 156–157
- home and environmental assessment, 157
- medical management, 158–159
- multidisciplinary team care, 159
- neuropsychology, 101
- nursing and community care, 158
- prevalence, 152
- Richardson’s syndrome (PSP-RS), 152–153
- speech and communication difficulties, 157
- tau protein pathology, 152
- therapeutic strategies, 156
- upper- and lower-limb functional issues, 157
- with features of frontotemporal dementia, 155
- propranolol, 30, 39
- PSP-corticobasal syndrome (PSP-CBS), 152
- PSP-parkinsonism (PSP-P), 152
- clinical features, 153–154
- diagnosis, 154
- PSP-progressive non-fluent aphasia (PNFA), 152
- PSP-pure akinesia with gait freezing (PAGF), 152
- clinical features, 154
- diagnosis, 154
- PSP-RS. See Richardson’s syndrome psychiatric testing, 99
- psychiatrist, 145
- psychological/emotional dimension of movement disorders, 126
- psychomotor dysfunction
  - Friedreich ataxia, 187
  - psychosis, 27, 33, 99
  - Purdue Pegboard, 98
  - Purkinje cells, 220
- putamen, 1
- quality of life (QOL), 233–234
- range of motion, 58, 61, 63, 64, 170, 176, 194, 215
Index

raphe nuclei, 3
rasagiline, 26
Recognition Memory for Faces test, 98
reflex sympathetic dystrophy, 48
rehabilitation
cerebral palsy, 134–136
children with chronic movement disorders, 134–136
hereditary spastic paraplegia, 134–136
multiple sclerosis, 133–134
Parkinson’s disease, 139–150
traumatic brain injury, 131–133
Rehabilitation Measures Database, 241
functions of the multidisciplinary team, 136–137
neuroplasticity and relearning capacity, 136
programs tailored to individual needs, 136–137
variability of clinical presentation, 136–137
reliability of outcome measurements, 234–236
religion/spiritual/existential dimension of health challenges, 127
REM sleep disorders, 88
resources for people with movement disorders, 128–129
responsiveness of outcome measures, 236
resting tremor, 46
Rett’s disorder, 217, 219
reward-related activities, 1
Richardson’s syndrome (PSP-RS), 152–3
rigidity, 1, 14, 25, 82, 152, 162
Ropinirole, 27
rotigotine, 28
Scales for Outcomes of Parkinson’s Disease – Cognition (SCOPA-COG), 99
Schedule for Assessment of Positive Symptoms, 99
secondary dystonia
functional neurosurgery, 39–40
secondary parkinsonism, 25
selective dorsal rhizotomy, 49
selegiline, 26
self-help groups, 128–129
sensory impairment, 82
serotonergic neurons, 3
sexual dysfunction, 88, 159
sialorrhea (excessive drooling), 85, 117, 158
sinemet, 145
single event multilevel surgery (SEMLS)
anesthesia, 207–208
analgiesia, 207–208
assistive devices required after surgery, 205–207
consent issues, 205
implant removal and fine tuning, 214
importance of postoperative rehabilitation, 203
indications in cerebral palsy patients, 203
inpatient stay, 207–210
post-operative 12 month gait laboratory reassessment, 213–214
post-operative equipment, 208–209
post-operative months 6–12, 213
post-operative positioning, 208–209
post-operative rehabilitation, 208–209
post-operative weeks 1–3, 210–211
post-operative weeks 3–6, 211
post-operative weeks 6–12, 212–213
post-operative weeks 12–24, 664–665
pre-operative baseline function assessment, 205
pre-operative diagnostic review, 205
pre-operative planning, 204–207
preparation for discharge, 209–210
rehabilitation stages, 203
what to expect in the second post-operative year, 215
single photon emission computed tomography
6-meter walk test, 82
skill learning, 104
sleep disorders, 88
social justice, 127
social work referral, 86
social worker
biological dimension of movement disorders, 126
biopsychosocial model, 126
building connections to resources, 128–129
commitment to social justice, 127
ecosystemic perspective, 126
family dimension of movement disorders, 127
links with self-help groups, 128–129
Mildred case study (Parkinson’s disease), 128
partnership with the client, 127
peer support, 127
psychological/emotional dimension of movement disorders, 126
religious/spiritual/existential dimension of health challenges, 127
role during the course of a disease, 128
role in supporting people with movement disorders, 124–125
role in the multidisciplinary team, 124–125
social/environmental dimension of health challenges, 127
work with people with Huntington’s disease, 125–126
work with people with Parkinson’s disease, 125
social/environmental dimension of health challenges, 127
sotalol, 30
spasmodic dysphonia, 39, 40, 44, 45, 112
rehabilitation strategies, 179
spasmotic torticollis, 39, 45
spastic dystonia
botulinum toxin treatment, 46
spastic dystonias, 45
Spastic Paraplegia Rating Scale (SPRS), 135
spasticity, 82
and equinovarus deformity, 187–188
lower limbs, 187–188
spasticity management intrathecal alcohol, 47
phenolization of peripheral nerves, 47
surgical procedures, 49
SPECT (single-photon emission computed tomography), 1
SPECT imaging
Huntington’s disease, 8–10
Parkinson’s disease, 5–6
speech difficulties. See SPECT in Friedreich ataxia, 186
parkinsonian syndromes, 157
speech disorders
dysarthria, 110–113
hyperkinetic dysarthria, 111–113
hypokineti dysarthria, 110–111
speech pathologist, 85, 86
approach to movement disorder rehabilitation, 110
assistive speech devices, 114
cognitive–linguistic disorders, 115–116
dysarthria assessment, 113–114
dysarthria treatment, 114
dysphagia in movement disorder patients, 116–118
hyperkinetic dysarthria, 111–113
hypokineti dysarthria, 110–111
role in movement disorder rehabilitation, 119
swallowing disorders, 116–118
use of technologies in service delivery, 118–119
speech therapist referral, 85
Index

Spielberger Stait-Trait Anxiety Inventory, 99
spinal cord, 19, 20, 47–9, 133, 135, 185, 188
spinal-cord injury, 192, 195
spinocerebellar ataxia, 25, 153
sport, 215, 222
status dystonicus, 31
Steele–Richardson–Olszewski syndrome, 152
stereotactic surgery, 5
stigma and movement disorders, 86
striatal GABAergic medium spiny neurons, 2–3, 8
striatum, 1–3
degeneration in Huntington’s disease, 8–11
stroke dystonias associated with, 45
Stroop test, 98, 100
substance P, 3
substantia nigra, 1–2
substantia nigra pars compacta, 14
substantia nigra pars reticulata, 14
subthalamic nucleus, 1–3, 14
Sudek’s atrophy, 48
supervisory attention system (SAS) concept, 95
supplementary motor area, 2, 7
surgical interventions role in movement disorder management, 36
See also functional neurosurgery; peripheral surgery; single event multilevel surgery (SEMLS).
swallowing disorders, 116–117
assessment, 117
management, 117–118
swallowing management and secretion management, 85–86
Friedreich ataxia, 195
synuclein immunocytochemistry, 4
tai chi, 134
Tardieu Scale, 190
tardive dyskinesia, 111, 112
tardive dystonia, 40
task-specific dystonias botulinum toxin treatment, 45–46
task-specific kinetic tremor, 30
tau protein pathology corticobasal degeneration, 155
progressive supranuclear palsy, 152
role in speech disorder rehabilitation, 118–119
telerhabilitation, 118
temporal processing, 103
Test of Language Competence – Expanded Edition (TLCE-E), 116
tetraabenazine, 33, 174
thalamotomy, 31, 39
thalamus, 1, 2, 3
The Word Test – Revised (TWTR), 116
thermal regulation disturbance, 87
tic disorders, 82, 111, 112
DSM-IV-TR criteria, 217
tics, 25
Timed Up and Go test (TUG), 83, 236
Tinneti Scale, 167
toe clawing, 188
tocolapse, 28
topiramate, 30, 39
torsion dystonia, 48
Tower of London test, 7, 98, 100
Trail Making test, 98
transcranial magnetic stimulation (TMS) 95
use in neuropsychology, 94–95
transcranial magnetic stimulation (TMS) studies
dystonia, 17–18
Gilles de la Tourette syndrome, 19
Huntington’s disease, 19
Parkinson’s disease, 15–16
transfer movements
physiotherapy interventions, 64
traumatic brain injury, 194
rehabilitation principles, 131–133
tremor, 25, 82, 111
action tremor, 30
botulinum toxin treatment, 46–47
cerebellar tremor, 30
classification, 30
clinical evaluation, 30
definition, 30
essential tremor treatment, 30–31
in Parkinson’s disease, 14
intention tremor, 30
isometric tremor, 30
kinetic tremor, 30
medical management, 30–31
position-specific postural tremor, 30
postural tremor, 30
rest tremor, 30
task-specific kinetic tremor, 30
training, 30–31
trihexyphenidyl, 26, 39
Unified Huntington’s Disease Rating Scale (UHDRS), 113, 168
Unified Parkinson’s Disease Rating Scale (UPDRS), 6, 83, 147, 148, 236
upper- and lower-limb function 157
parkinsonian syndromes, 157
upper-limb dysfunction
physiotherapy interventions, 64
urinary-tract infections, 89
utilization behavior, 103
validity of outcome measurements, 236
vascular parkinsonism, 25, 152, 153
dysphagia management, 157–158
gait and mobility rehabilitation issues, 156–157
home and environmental assessment, 157
medical management, 158–159
multidisciplinary team care, 159
nursing and community care, 158
speech and communication difficulties, 157
therapeutic strategies, 156
upper- and lower-limb functional issues, 157
verbal fluency tests, 100
vestibular dysfunction, 82
visual problems
in Friedreich ataxia, 187
visuo-spatial function tests, 98
vocal tics, 112
voice tremor, 113
wearing-off effect with levodopa, 28
Wechsler Adult Intelligence Scales (WAIS-III or IV), 98
WEMOVE web page, 241
Western Aphasia Battery – Revised (WAB-R), 116
Wiig-Semel Test of Linguistic Concepts (WSTLC), 116
Wilson’s disease, 25, 153
Wisconsin card sorting test, 98, 100
working memory model (Baddeley), 95
working memory tests, 98
writer’s cramp, 39, 45
botulinum toxin treatment, 45–46
rehabilitation strategies, 177–178
yoga, 134
zonisamide, 30
Zung Self-rating Anxiety Scale, 99

© in this web service Cambridge University Press

www.cambridge.org